'Exogenous insulin' presentation slideshows

Management of Common Comorbidities in Diabetes

Management of Common Comorbidities in Diabetes. Management of Common Comorbidities in Diabetes. Obesity. Prevalence of Obesity in Type 2 Diabetes. NHANES 1999-2004 (N=984). Normal (BMI <25). 12%. Overweight (BMI 25-29). 27%. T2DM Patients (%). Obese (BMI ?30). 61%.

912 views • 70 slides

DISCUSSION

DISCUSSION. Anatomy. Pancreas: head, uncinate process, neck, body, tail Pancreatic duct ( Wirsung ): joins the CBD at ampulla of Vater ? enters 2 nd part of duodenum at duodenal papillae Accessory duct ( Santorini ): opens into the duodenum. Anatomy. Pancreatic gland: Lobulated

381 views • 22 slides

DIABETES MELLITUS

BIOCHEMISTRY

267 views • 18 slides

Therapy for Type II Diabetes

Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics. -. -. -. Peripheral glucose uptake. 1.Pancreatic insulin Secretion: Incretin, ranolazine. 5. Gut CHO Absorption: Incretin, Pramlintide,

106 views • 10 slides

Practical Implementation as a Discussion with the Patient

Practical Implementation as a Discussion with the Patient. Practical Use of SGLT-2 Inhibitors in T2DM: Clinical Pearls- Perlas de Sabiduria. Stan Schwartz MD, FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor of Medicine, U of Pa. stschwar@gmail.com.

109 views • 10 slides

In T2DM, ?-Cell Mass in Islets is Significantly Reduced

105 views • 10 slides

Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 Innovative and Diversified Pipeline

Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations market research report is the latest addition to RnRMarketResearch.com and its collection of therapeutics business intelligence reports aimed to help take better decisions

140 views • 5 slides

Supplementary Figure 1A

Supplementary Figure 1A. Patients with HCC. Patients with No HCC. Model building n = 255. 14.5 %. Yes. No. HBV. n = 35. n = 220. 10.0 %. 42. %. Male. Female. Group 1. Sex. n = 100. n = 120. 3.0 %. 15.8%. Yes. No. Group 2. Exogenous insulin. n = 13. n = 107.

141 views • 4 slides